Navigation Links
NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
Date:7/18/2013

SOUTH SAN FRANCISCO, Calif., July 18, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today the successful completion of a $50 million Series C financing to support advancing its portfolio of potential therapeutics for the treatment of diabetes, obesity and other cardio-metabolic diseases. 

Several new investors participated in the Series C financing, including the Topspin Fund, an investment group comprised of James Simons, Leo A. Guthart, Andy Gyenes and Steven Winick.  The financing also included participation from our existing investors, including The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures.  With the Series C financing, NGM has raised over $130 million since the company's founding in 2008.

"With this $50 million round of equity financing, coupled with non-dilutive capital from our collaborations with Daiichi Sankyo, Janssen, MedImmune and JDRF, NGM is well-positioned to advance the promising pipeline of candidates generated by our drug discovery efforts," said William J. Rieflin, Chief Executive Officer of NGM.  "We remain focused on delivering the next generation of first-in-class therapeutics for the treatment of diabetes and other cardio-metabolic diseases."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases.  NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.  For more information, please visit the company's website at www.ngmbio.com.


'/>"/>
SOURCE NGM Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
8. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... April 01, 2020 , ... Dr. Michele S. Green, ... the esteemed Haute Beauty network. , The Haute Beauty Network, well known for ... leading Anti-Aging Expert. , Haute Beauty offers a prominent collective of leading doctors ...
(Date:3/30/2020)... ... 2020 , ... Energage, the leader in helping organizations establish ... of survey question packs that enable organizations to keep the lines of communication ... current situation continues to evolve, The Energage Operational Readiness Survey Packs offer scientifically ...
(Date:3/30/2020)... , ... March 30, 2020 , ... ... Aspire Regenerative now offers telemedicine appointments in addition to in-person visits. ... that the safety and well-being of patients, health care professionals, and the community ...
Breaking Medicine Technology:
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, An FDAnews ... , What change management method should one be using for a medical ... on the type of change. Is it due to post-market design change, production process ...
(Date:4/1/2020)... ... April 01, 2020 , ... American hospital workers are ... Coronavirus-infected patients. , Staffers are in particular need of face shields, which protect ... The Wall Street Journal reported that New York City mayor Bill de Blasio's ...
(Date:4/1/2020)... ... April 01, 2020 , ... Global mobile data platform provider Zerion ... adjusting to new needs based on COVID-19. , As cases continue to rise across ... types. , Zerion will extend support by offering free basic iFormBuilder accounts and forms ...
(Date:3/30/2020)... SAN DIEGO (PRWEB) , ... March 30, 2020 ... ... to new and prospective patients, continuing its commitment to provide comprehensive and ... , Patients can use Achieve Medical Center’s UpDox platform for telemedicine services ...
(Date:3/28/2020)... ... March 27, 2020 , ... Suntuity AirWorks ... of companies, is mobilizing their drone equipment and training personnel to help towns ... DJI Enterprise level Matrice and Agras drones, Suntuity AirWorks is mobilizing their drone ...
Breaking Medicine News(10 mins):